FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2177-2179 May 18, 2006 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Pritchard, K. I. PubMed Citation

Adjuvant chemotherapy and hormonal treatment have substantially reduced the risks of relapse and death that threaten a woman for many years after the diagnosis of breast cancer.¹ Progress in breast-cancer treatment is due in part to the incorporation of powerful cytotoxic agents into chemotherapy regimens and to the optimization of the schedules of administration of these agents. Anthracycline-based chemotherapy combinations, such as the cyclophosphamide–epirubicin–fluorouracil (CEF) regimen evaluated in the National Cancer Institute of Canada Clinical Trials Group Mammary.5 (MA.5) study,² when compared with the regimen of cyclophosphamide, methotrexate, and fluorouracil (CMF), produce on average a further relative reduction in deaths . . . [Full Text of this Article]

Source Information

From the Jules Bordet Institute, Université Libre de Bruxelles, Brussels.

Related Letters:

Anthracyclines in Early Breast Cancer
Wilson K. S., Pritchard K. I., Bramwell V. H., Levine M. N., the National Cancer Institute of Canada Clinical Trials Group , Piccart-Gebhart M. J.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:845-846, Aug 24, 2006. Correspondence

This article has been cited by other articles:

• Hartmann, O., Spyratos, F., Harbeck, N., Dietrich, D., Fassbender, A., Schmitt, M., Eppenberger-Castori, S., Vuaroqueaux, V., Lerebours, F., Welzel, K., Maier, S., Plum, A., Niemann, S., Foekens, J. A., Lesche, R., Martens, J. W.M. (2009). DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy. Clin. Cancer Res. 15: 315-323 [Abstract] [Full Text]  
• Bartlett, J. M.S., Munro, A., Cameron, D. A., Thomas, J., Prescott, R., Twelves, C. J. (2008). Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial. JCO 26: 5027-5035 [Abstract] [Full Text]  
• Wilson, K. S., Pritchard, K. I., Bramwell, V. H., Levine, M. N., the National Cancer Institute of Canada Clinical T, , Piccart-Gebhart, M. J. (2006). Anthracyclines in Early Breast Cancer. NEJM 355: 845-846 [Full Text]  
• (2006). Is Tailoring of Chemotherapy in HER2-Positive Breast Cancer Feasible?. JWatch Women's Health 2006: 9-9 [Full Text]